机译:高敏感性心肌肌钙蛋白T可早期预测可疑急性冠脉综合征患者发展中的非ST段抬高型心肌梗塞,且入院时肌钙蛋白阴性
Evangelos Giannitsis,1* Meike Becker,1 Kerstin Kurz,1 Georg Hess,2 Dietmar Zdunek,1 and Hugo A. Katus11 Medizinische Klinik, Abteilung für Innere Medizin III, Universitätsklinikum Heidelberg, Heidelberg, Germany, 2 Roche Diagnostics, Nonnenwald 2, Penzberg, Germany.* Address correspondence to this author at: Medizinische Klinik III, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Fax +49-6221-56-5516, e-mail evangelos_giannitsis@med.uni-heidelberg.de.Received July 22, 2009, accepted January 19, 2010.Previously published online at DOI: 10.1373/clinchem.2009.134460Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: G. Hess, Roche Diagnostics, D. Zdunek, Roche Diagnostics.Consultant or Advisory Role: G. Hess, Roche Diagnostics, E. Giannitsis, Roche Diagnostics.Stock Ownership: None declared.Honoraria: E. Giannitsis, Roche Diagnostics and Mitsubishi Chemicals, H.A. Katus, Roche Diagnostics.Research Funding: E. Giannitsis, Roche Diagnostics. H.A. Katus, Roche Diagnostics, AstraZeneca, Bayer Vital, and Lilly Germany. The investigations were supported by Roche Diagnostics, Germany, which provided hs-cTnT assays.Expert Testimony: None declared.Other: H.A. Katus developed the cTnT assay and holds a patent jointly with Roche Diagnostics.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.,;
机译:高敏性心肌肌钙蛋白T可早期预测疑似急性冠状动脉综合征和入院时肌钙蛋白阴性的患者发生的非ST段抬高型心肌梗塞。
机译:高敏感性心肌肌钙蛋白T可早期预测可疑急性冠脉综合征患者发展中的非ST段抬高型心肌梗塞,且入院时肌钙蛋白阴性
机译:高敏性心肌肌钙蛋白T的特定年龄99%临界值用于早期预测中年患者的非ST段抬高型心肌梗死(NSTEMI)
机译:非ST段升高急性心肌梗死患者冠状动脉疾病的TIMI风险分数和严重程度。
机译:肾功能减退的日本人高敏感性心肌肌钙蛋白,成纤维细胞生长因子23与左心室肥厚的关系
机译:在串行测试中使用当代和高灵敏度心肌肌钙蛋白测定(与作为比较者的单样本测试相比)对疑似急性非ST段抬高型心肌梗死的患者的诊断准确性:系统评价方案
机译:在使用新的扩张型心肌病的患者缓和EPOSTERS1385Longitudinal应变评估加速DENSE sequence1407Simultaneous T1和T2与CABIRIA心脏定量:在4维流动的加速算法初始临床experience1423Head对头比较CMR1502Left心室功能和尺寸由混合心脏正电子发射断层摄影术评价 - 磁性共振:由两个modalities1510Left庭派生左室射血分数和心室体积的个体间的比较,在1.5和3特斯拉评估心血管磁共振 - 免费的年龄和性别effects1514Comparison呼吸心脏MRI径向技术标准的多屏气电影SSFP CMR技术的LV卷和Function1536Self-导航自由呼吸各向同性3D整个心脏相位敏感反转恢复磁共振导航仪没有检测右Ventricu心肌infarction1547Assessment的评估拉尔菌株使用心肌变形恢复半自动技术:初步经验和正常Values1586Tissue跟踪心肌变形分析和预测左室重构急性心肌infarction1589Investigating策略优化31P MRS临床心脏在3T:初始Results1620Quantitative标准的先天缺失的诊断心包心脏磁Resonance1632Widespread组织损伤急性心肌梗死时:证据先进CMR relaxometry1322Computed CT冠状动脉成像与压力心脏磁共振对症的管理吻合血管患者:成本效益研究(战略研究)1339Comparison低与高剂量钆布醇在1.5特斯拉晚钆增强成像的临床可行性,在中间型地贫心脏并发症的预测study1347Multi参数心脏核磁共振的前瞻性德穆尔心血管磁共振的ticenter Study1461Prognostic价值衍生心肌纤维化指标在住院的急性期CMR的心脏移植recipients1523The作用:改变基于CMR-paradigms1542Preoperative比分预测缺血性心脏衰竭patients1555Excellent响应速度外科左心室重建心脏再同步化后心室反应治疗与磁共振imaging1626The ECG导引作为心脏磁共振成像致心律失常性基板的在ST段抬高心肌infarction1340Pathological在风险评估经历在3.0T CMR T1映射的室性早搏contractions1649Comparison和血管造影APPROACH分数区域消融患者的预测左束支传导疾病的患者与非缺血性心肌病相关因素:心血管磁共振study1342Myocardial重塑和纤维化nonischaemic扩张型心肌病:在从在由心血管磁性resonance1622Persistent心肌炎症评估肥厚型心肌病的纤维化和收缩功能障碍之间心血管磁性resonance1411The协会由于心肌内出血景点在再灌注STEMI为先导,以不利的LV重塑 - 从低的多参数mapping1566Semiquantitative分析和高的b值DWI的见解为在心脏MRI检测冠状动脉疾病急性myocarditis1567Value在结节性硬化症complex1578Papillary肌肉初诊收缩期Dysfunction1570Usefulness心脏磁共振检测心肌水肿提供进一步的深入了解肥大心脏:心血管磁共振study1627Diagnostic和CMR定时的临床意义(早期与晚)患者肌钙蛋白阳性的急性冠脉综合征和通畅的冠状动脉:表1。